ACH Accendra Health, Inc. - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
ACH Stock | Fundamental Analysis & Investment Insights
NYSE
Healthcare
Medical Distribution
Current Price
Live
$2.11
Analyst Target
$4.08
+93.5%
Upside
52W High
$15.54
52W Low
$1.84
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$163.2M
P/E
N/A
ROE
-196.4%
Profit margin
-12.4%
Debt/Equity
N/A
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
88%
Analysis Accuracy
The Advanced Deterministic Scorecard reveals a critically weak financial health profile with a Piotroski F-Score of just 1/9, indicating severe operational and financial distress. Despite a low forward P/E of 2.25 and a Price/Sales ratio of 0.02 suggesting apparent cheapness, negative profitability metrics—including a -12.45% profit margin and -196.39% ROE—undermine valuation appeal. The company faces acute liquidity risk with a current ratio of 0.86 and a near-zero quick ratio of 0.10, while earnings have collapsed with a YoY decline of 40.5%. Although insider sentiment is neutral and analysts project a 92% upside to a $4.08 target, the deteriorating fundamentals and lack of cash flow transparency present substantial risk.
Key Strengths
Low forward P/E of 2.25 may attract contrarian or value-seeking investors
Operating margin of 8.08% indicates some pricing power or cost control at operational level
Gross margin of 20.78% is relatively healthy for medical distribution sector
Analyst target price implies 92% upside from current levels, suggesting potential undervaluation
Recent quarters show mixed but occasionally strong earnings surprises, including +17.3% in Q4 2023
Key Risks
Piotroski F-Score of 1/9 signals extreme financial weakness and high risk of continued underperformance
Negative Price/Book of -0.38 and unreported Altman Z-Score indicate likely insolvency risk or balance sheet instability
Current and quick ratios (0.86 and 0.10) suggest imminent liquidity crisis and inability to meet short-term obligations
ROE of -196.39% reflects severe erosion of shareholder equity, likely due to accumulated losses or debt burden
Revenue growth of only 1.5% YoY combined with declining earnings signals stagnation and weakening business model
AI Fair Value Estimate
Based on comprehensive analysis
$4.08
+93.4% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
25
Weak
58
22
34
10
0
AI Verdict
Highly bearish due to catastrophic financial health and deteriorating earnings, despite low valuation multiples
Key drivers: Piotroski F-Score of 1/9, Negative ROE and Price/Book, Collapsing earnings and revenue growth, Critical liquidity constraints, Lack of cash flow and debt transparency
Confidence
90%
Value
58/100
Ref P/E, PEG, Graham Number
Positives
- Forward P/E of 2.25 is exceptionally low
- Price/Sales of 0.02 suggests deep discount relative to sales
Watchpoints
- Negative book value invalidates traditional valuation models
- No Graham Number due to unprofitability
Future
22/100
Ref Growth rates
Positives
- Analyst target implies significant upside
- Some recent earnings beats provide marginal optimism
Watchpoints
- YoY EPS growth down 40.5%
- Q/Q EPS down 3.8%
- Revenue growth nearly flat at 1.5%
Past
34/100
Ref Historical trends
Positives
- History of frequent earnings beats prior to recent downturn
- Strong EPS surprises in 2020–2022 period
Watchpoints
- Earnings trajectory has sharply reversed since 2022
- Profitability deteriorating over time
Health
10/100
Ref Altman Z-Score, Piotroski F-Score
Positives
No standout positives identified.
Watchpoints
- Piotroski F-Score of 1/9 indicates severe financial distress
- Current ratio of 0.86 below safety threshold
- Quick ratio of 0.10 indicates near-term liquidity crisis
- ROE of -196.39% reflects capital destruction
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- Dividend Strength of 0/100
- No dividend yield or payout history
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$2.11
Analyst Target
$4.08
Upside/Downside
+93.5%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ACH and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ACH
Accendra Health, Inc.
Primary
|
-92.8% | -89.2% | -85.8% | -73.2% | -22.1% | -16.3% |
|
APYX
Apyx Medical Corporation
Peer
|
-63.3% | +11.5% | +179.1% | +78.0% | +12.1% | -3.5% |
|
ANIK
Anika Therapeutics, Inc.
Peer
|
-72.8% | -67.0% | -41.2% | +29.0% | +6.3% | +13.3% |
|
ADAG
Adagene Inc.
Peer
|
-88.0% | +82.6% | +53.9% | +31.4% | +85.8% | -3.4% |
|
ACB
Aurora Cannabis Inc.
Peer
|
-96.8% | -57.7% | -35.7% | -24.4% | -11.1% | +6.2% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
2.25
PEG Ratio
N/A
P/B Ratio
-0.38
P/S Ratio
0.02
EV/Revenue
0.22
EV/EBITDA
4.68
Market Cap
$163.2M
Profitability
Profit margins and return metrics
Profit Margin
-12.45%
Operating Margin
8.08%
Gross Margin
20.78%
ROE
-196.39%
ROA
3.75%
Growth
Revenue and earnings growth rates
Revenue Growth
+1.5%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
N/A
Current Ratio
0.86
Weak
Quick Ratio
0.1
Poor
Cash/Share
$0.42
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-27
$N/A
2025-10-30
$0.25
+6.4% surprise
2025-08-11
$0.26
-5.7% surprise
2025-05-08
$0.23
+14.4% surprise
Healthcare Sector Comparison
Comparing ACH against 146 companies in the Healthcare sector
(11 bullish, 60 neutral, 75 bearish)
Return on Equity (ROE)
-196.39%
This Stock
vs
-56.86%
Sector Avg
+245.4%
(Excellent)
Profit Margin
-12.45%
This Stock
vs
-20.8%
Sector Avg
-40.2%
(Weaker)
Revenue Growth
1.5%
This Stock
vs
62.23%
Sector Avg
-97.6%
(Slower)
Current Ratio
0.86
This Stock
vs
3.45
Sector Avg
-75.0%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ACH
Accendra Health, Inc.
|
BEARISH | $163.2M | - | -196.4% | -12.4% | $2.11 | |
|
APYX
Apyx Medical Corporation
|
BEARISH | $159.19M | - | -168.1% | -30.4% | $3.88 | |
|
ANIK
Anika Therapeutics, Inc.
|
BEARISH | $150.85M | - | -8.7% | -29.3% | $10.46 | |
|
ADAG
Adagene Inc.
|
BULLISH | $147.99M | - | -63.3% | -% | $3.14 | |
|
ACB
Aurora Cannabis Inc.
|
BEARISH | $213.79M | - | -15.5% | -22.5% | $3.77 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-11-19 | LONG ANDREW G. | Chief Executive Officer | Gift | 47,908 | - |
| 2025-08-14 | COLISEUM CAPITAL MANAGEMENT, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | 1,537,852 | $8,099,544 |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
6 analysts
Citigroup
2026-01-09
Buy
Buy
UBS
2025-11-03
Buy
Neutral
JP Morgan
2025-08-27
Underweight
Underweight
UBS
2025-08-13
Buy
Buy
Baird
2025-08-12
Outperform
Outperform
Citigroup
2025-08-12
Buy
Buy
B of A Securities
2025-08-12
Underperform
Underperform
Past News Coverage
Recent headlines mentioning ACH from our newsroom.
Newest → oldest
No matching news yet.